Taysha Gene Therapies Aktie
WKN DE: A2QCJL / ISIN: US8776191061
|
15.05.2025 16:34:05
|
Taysha Gene Therapies, Inc. Q1 Loss Decreases, Beats Estimates
(RTTNews) - Taysha Gene Therapies, Inc. (TSHA) revealed Loss for first quarter that decreased from last year and beat the Street estimates.
The company's bottom line totaled -$21.53 million, or -$0.08 per share. This compares with -$24.06 million, or -$0.10 per share, last year.
Analysts on average had expected the company to earn -$0.09 per share. Analysts' estimates typically exclude special items.
The company's revenue for the period fell 32.6% to $2.30 million from $3.41 million last year.
Taysha Gene Therapies, Inc. earnings at a glance (GAAP) :
-Earnings: -$21.53 Mln. vs. -$24.06 Mln. last year. -EPS: -$0.08 vs. -$0.10 last year. -Revenue: $2.30 Mln vs. $3.41 Mln last year.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Taysha Gene Therapies Inc Registered Shsmehr Nachrichten
|
11.08.25 |
Ausblick: Taysha Gene Therapies vermeldet Zahlen zum jüngsten Quartal (finanzen.net) | |
|
14.05.25 |
Ausblick: Taysha Gene Therapies informiert über die jüngsten Quartalsergebnisse (finanzen.net) |
Analysen zu Taysha Gene Therapies Inc Registered Shsmehr Analysen
Aktien in diesem Artikel
| Taysha Gene Therapies Inc Registered Shs | 4,96 | 1,02% |
|